PATENT CLAIM ANALYSIS

Application Number: 15946625
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "141100"]

Abstract:
The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.

Claim (Index 21):
The isolated antibody of  claim 18 , wherein the antibody has one or more of the following characteristics:\n (a) binds to human T cells with an EC50 of about 0.7 nM and cynomolgus T cells with an EC50 of about 0.3 nM; (b) binds to human activated CD4+ T cells; (c) does not bind to human CD28 or human CTLA-4; (d) activates at least one primary T lymphocyte; (e) induces phosphorylation of protein kinase B (pAkt) in an in vitro primary T cell signaling assay with an EC50 of about 30 nM; (f) induces interleukin-10 (IL-10) production in response to staphylococcal enterotoxin B in a Tfh and naive B cell co-culture assay; (g) induces a greater proliferation increase of CD3-stimulated Teffs compared to CD45RA+ Tregs and CD45RO+ Tregs in an in vitro assay; (h) reduces Teff suppression by Tregs; (i) wherein 10 \u03bcg/mL of the antibody does not increase cytokine production in a whole blood cell assay; (j) increases secretion of at least one of IL-10 and IFN-\u03b3 by Tfh cells in vitro; (k) stimulates ICOS-mediated signaling; (l) has increased affinity for CD32B and/or CD32A; and/or (m) has decreased affinity for CD16.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 91.0
- Lexical Diversity: 2.06897
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15166114', '15474731', '15646558', '14949424', '14994828']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7955129004265252
- 35 USC 102 Novelty (BERT): 0.5817630652573985
- Combined Prediction Score: 0.7741379169096125
- Mean Citation Score: 498.218734
- Max Citation Score: 511.36288
- Similarity Product: 381.88790465633394

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test